Pharmacists in Fort Dodge, Iowa


29 Pharmacists found in Fort Dodge
male pharmacist

John Daniel


Pharmacist
1114 Central Ave, Fort Dodge, IA 50501
515-573-3431     515-573-4116

male pharmacist

Dr. John F Daniel Iii, PHARM.D


Pharmacist
1114 Central Ave, Fort Dodge, IA 50501
515-573-3431     515-573-4116

female pharmacist

Kristine Ugboh, PHARMD, RPH


Pharmacist
115 S 29th St, Fort Dodge, IA 50501
515-576-5320    



male pharmacist

Dr. Lance T Platt Jr., PHARM.D.


Pharmacist
2910 1st Ave S, Fort Dodge, IA 50501
515-573-7202     515-398-0019

female pharmacist

Dr. Lisa Marie Flaherty


Pharmacist
1114 Central Ave, Fort Dodge, IA 50501
515-573-3431    

female pharmacist

Mrs. Marta Karyn Kramer, R.PH


Pharmacist
1428 2nd Ave No., Fort Dodge, IA 50501
515-955-5430     515-955-1453

female pharmacist

Dr. Mikaela M Newlun, PHARMD


Pharmacist
2326 19th Ave N, Fort Dodge, IA 50501
402-469-0124    

female pharmacist

Min Hee Kang


Pharmacist
1114 Central Ave, Fort Dodge, IA 50501
515-573-3431    

female pharmacist

Nicole Friesth, PHARM.D.


Pharmacist
2910 1st Ave S, Fort Dodge, IA 50501
515-573-7202    

male pharmacist

Steven Bartlett


Pharmacist
2503 5th Ave S, Fort Dodge, IA 50501
515-576-7113    

female pharmacist

Theresa Doyle, PHARMD


Pharmacist
1114 Central Ave, Fort Dodge, IA 50501
515-573-3431     515-573-4116

male pharmacist

Mr. Thomas F Donner, RPH.


Pharmacist
115 S 29th St, Fort Dodge, IA 50501
515-576-5320     515-576-4078

male pharmacist

Timothy Richard Bormann


Pharmacist
115 S 29th St, Fort Dodge, IA 50501
515-576-5320     515-576-4078


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.